Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider

About this book

This book is designed to familiarize clinical practitioners in systemic therapy options and medical management of urologic malignancies including prostate cancer, bladder and upper tract urothelial carcinoma, and renal cell carcinoma. Organized by organ system, the text highlights new therapies such as novel forms of androgen deprivation, cytotoxic chemotherapy, immune check point and immunomodulatory agents, and targeted therapies. Written by experts in the field, the book also reviews current chemotherapy and immunotherapy regimens for genitourinary malignancies and discusses indications, outcomes, and toxicities, as well as clinical trial concepts. Each of the book’s chapters offers a bulleted box of clinical pearls on the particular role of the APP.

Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider is a resource for urologists, uro-radiologists, medical clinicians and family practitioners alike, familiarizing its audiences with systemic therapy regimens for urologic malignancies, as well as their expected outcomes and side effects.

Table of contents (25 chapters)

Introduction: Integration of APP into Urologic Oncology Practice

Pages 1-3

Gomella, Leonard G.

Overview and Active Surveillance of Prostate Cancer

Pages 7-19

Izes, Joseph K. (et al.)

Monitoring and Managing Men Following Initial Treatment of Prostate Cancer

Pages 21-28

Sims, Terran W. (et al.)

Radical Prostatectomy and Survivorship After Radical Prostatectomy

Pages 29-41

Anderson, Courtney C. (et al.)

Multimodal Treatment Plans in Prostate Cancer

Pages 43-53

Flanagan, Rachel Lin (et al.)

Radiotherapy for Prostate Cancer

Pages 55-75

Donnelly, Ann E. (et al.)

Androgen Deprivation Therapy

Pages 77-92

Reyes, Charlene (et al.)

Second-Generation Androgen-Targeted Agents

Pages 93-103

Gurten, Laura P. (et al.)

Chemotherapy and Prostate Cancer

Pages 105-118

Tsang, Miranda L.

Radiopharmaceuticals for Prostate Cancer

Pages 119-132

Donnelly, Ann E. (et al.)

Immunotherapy and Novel Agents on the Horizon for the Treatment of Prostate Cancer

Pages 133-138

Barron, Suzanne (et al.)

Bladder Cancer: Overview, Epidemiology, Initial Presentation and Diagnosis

Pages 141-157

Avinash, Betsy M. (et al.)

Intravesical Therapy for Non-muscle Invasive Urothelial Carcinoma

Pages 159-168

Hassen, Waleed (et al.)

Bladder Cancer: Muscle-Invasive Disease, Neoadjuvant Chemotherapy, and Radical Cystectomy

Pages 169-185

Dunn, Mary W. (et al.)

Chemoradiation Bladder Preservation

Pages 187-192

Caruso, Adele Marie (et al.)

Metastatic Bladder Cancer and the Use of Cisplatin Chemotherapy

Pages 193-200

Mille, Patrick (et al.)

Immunotherapy for Metastatic Urothelial Cancer

Pages 201-213

Gray, Javaughn Corey R. (et al.)

Novel and Experimental Strategies in the Treatment of Metastatic Urothelial Carcinoma

Pages 215-220

Izes, Joseph K. (et al.)

Upper Tract Urothelial Carcinoma

Pages 221-228

Lizardi-Calvaresi, Anne E. (et al.)

Kidney Cancer and Its Treatment

Pages 231-237

Dreyzin, Elena (et al.)

Targeted Therapies for Treatment of Metastatic Renal Cell Carcinoma

Pages 239-254

Matande, Jessica (et al.)

Immune Therapies for Metastatic Kidney Cancer

Pages 255-269

Faraj, Kassem S. (et al.)

Novel Therapies for Renal Cell Carcinoma

Pages 271-275

Zilinskas, Brooke

Testicular Cancer

Pages 279-293

Cossis, Kara R. (et al.)

Penile Cancer

Pages 295-302

Mark, J. Ryan (et al.)